News
SB 11 filed with EMA for retinal vascular disorders.- Samsung Bioepis + Biogen
Samsung Bioepis and Biogen announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for SB 11 (ranibizumab biosimilar) referencing Lucentis. Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular disorders, which are a leading cause of blindness. Samsung Bioepis announced in November 2019 that it entered into a new commercialization agreement with Biogen for two ophthalmology biosimilar candidates, SB11 (ranibizumab) and SB15 (aflibercept), in the United States (U.S.), Canada, Europe, Japan and Australia.
Condition: Age Related Macular Degeneration
Type: drug